Sorrento Therapeutics, Inc, a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease ...

Stock analysts at StockNews.com initiated coverage on shares of Sorrento Therapeutics (NASDAQ:SRNE – Get Free Report) in a report released on Thursday. The firm set a “hold” rating on the ...

US Bankruptcy Court for the Southern District of Texas issued an order to extend the lock-up period on the Scilex Dividend Stock, previously distributed by Sorrento, to April 14, 2025.Accordingly ...

Market Open. US Bankruptcy Court for the Southern District of Texas issued an order to extend the lock-up period on the Scilex Dividend Stock, previously distributed by Sorrento, to April 14, ...

Shares in Sorrento Therapeutics rose 158% on Friday after it revealed plans to start human trials of an antibody therapy that achieved complete inhibition of the coronavirus in preclinical studies.

Health-Related Quality of Life for Persons Treated or Monitored for Anal High-Grade Squamous Intraepithelial Lesions (AMC-A01) The management of renal cell carcinoma (RCC) has seen significant ...

Copyright © 2025 MarketWatch, Inc. All rights reserved.

Local biotech Aardvark Therapeutics made its debut on the public market this month, making it San Diego’s first life science ...